KalVista Pharmaceuticals, Inc. (KALV)

KalVista Pharmaceuticals' stock price has been significantly impacted by several key events over the past six months. The stock price increased by 85.81% from April 4, 2025, to April 2, 2026. The FDA approval of EKTERLY (sebetralstat) on July 7, 2025, and its subsequent commercial launch in the U.S. and other countries, positively influenced the stock. The company reported $49.1 million in global net product revenue for EKTERLY for the eight months ended December 31, 2025. Positive interim Phase 3 data from the KONFIDENT-KID trial of EKTERLY for children aged 2-11 years was announced on March 30, 2026.

There appears to be some seasonality in the demand for KalVista Pharmaceuticals' products. Prescription refills for EKTERLY surpassed initial prescriptions in the fourth quarter of 2025, potentially reflecting demand pulled forward ahead of the holidays. Seasonality analysis of KALV's historical stock price data indicates that June has the highest probability of positive returns at 66.67%.

KalVista Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing oral therapies for rare diseases, particularly hereditary angioedema (HAE). Their major product is EKTERLY (sebetralstat), an FDA-approved oral treatment for acute HAE attacks. The company also has preclinical programs for oral Factor XIIa inhibitors for prophylactic treatment of HAE and other conditions.

KalVista Pharmaceuticals has a global presence with its headquarters in Framingham, Massachusetts, USA. Research operations are in Porton Down, Wiltshire, UK, and development activities are in Salt Lake City, Utah, USA. The company also has international operations in Zug, Switzerland, and Tokyo, Japan. EKTERLY has received regulatory approvals in multiple major markets, including the United States, European Union, United Kingdom, Switzerland, Australia, Singapore, and Japan.

KalVista Pharmaceuticals' brand reputation has been positively influenced by the successful development and commercialization of EKTERLY. The FDA approval and subsequent launches boosted the company's standing. The rapid adoption of EKTERLY indicates strong market acceptance. Positive interim Phase 3 data from the KONFIDENT-KID trial further enhances the company's reputation.

KalVista Pharmaceuticals, Inc. has an ownership structure predominantly held by institutional investors. As of April 8, 2026, there were 163 institutional owners and shareholders holding a total of 67,326,813 shares. Major institutional owners include VR Adviser, LLC, Frazier Life Sciences Management, L.P., Suvretta Capital Management, LLC, Tang Capital Management LLC, BlackRock, Inc., Millennium Management Llc, Capital World Investors, Vanguard Group Inc, Silverarc Capital Management, Llc, and Point72 Asset Management, L.P.